{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-001642","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2023-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.712464+00:00","generated_at":"2026-06-19T06:43:01.206975+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aytu BioPharma Q2 FY2023 revenue $26.3M (+14% YoY); second consecutive positive adjusted EBITDA $0.7M","bullets":["Net revenue $26.3M, up 14% YoY; Rx segment $18.0M (+23%) driven by 95% growth in pediatric products.","Adjusted EBITDA positive $0.7M vs $(7.6)M loss in year-ago quarter; second consecutive positive quarter.","Net loss $(6.7)M ($2.15 per share) improved from $(11.5)M ($8.74 per share) in Q2 FY2022.","Gross margin expanded to 66% from 53% YoY; suspension of clinical programs expected to save over $20M.","Extended interest-only period on Avenue loan to Jan 2024; 1-for-20 reverse stock split regained Nasdaq compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-001642","json":"https://secwatch.observer/filing/0001558370-23-001642.json","markdown":"https://secwatch.observer/filing/0001558370-23-001642.md","text":"https://secwatch.observer/filing/0001558370-23-001642.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023001642/0001558370-23-001642-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023001642/aytu-20230221x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T06:43:01.206975+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d1b4e0f3ec276ec5fa135d40158df0397ead6fb2","claim":"AYTU BIOPHARMA, INC reported the quarter ended December 31, 2022 results: revenue $26.3 million.","evidence_excerpt":"​ --- EX-99.1 (EX-99.1) --- ​ ​ Aytu BioPharma Reports Second Quarter of Fiscal Year 2023 ​ Second Consecutive Quarter of Positive Adjusted EBITDA ​ Quarterly Net Revenue of $26.3 Million Driven by 23% Growth in Rx Segment ​ Company to Host Conference Call Today at 5:00 pm ET ​ ENGLEWOOD, CO / February 21, 2023 / Aytu BioPharma, Inc. (the Company or “Aytu”)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023001642/0001558370-23-001642-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2022"},{"label":"Revenue","value":"$26.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}